Thursday, January 21, 2021 11:26:20 PM
Zelira Therapeutics (ASX:ZLD) (OTCQB: ZLDAF) inked a licensing deal with Washington DC-based Alternative Solutions to produce and distribute HOPE throughout the district. Dr. Oludare Odumosu, CEO and Managing Director of USA for Zelira, told Benzinga that Zelira’s search for a DC license partner for HOPE was much more strategic than simply having visibility in the nation’s capital, and is a tentpole for Zelira’s overall US growth efforts for 2021.
“This latest partnership with Alternative Solutions aligns with Zelira’s long-stated mission to work with market leaders in each approved market to expand access to HOPE across the US,” said Odumosu. The first products are set to debut on Washington DC dispensary shelves in the Spring of 2021.
MADlONG2029
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM